Survival of patients with colorectal cancer liver metastases treated by regional chemotherapy

Hepato-Gastroenterology

Volumn 53, Issue 69, 2006, Pages 426-434

  Melichar, Bohuslav ^a   Voboril, Zbynek ^a   Cerman Jr , Jaroslav ^a   Melicharová, Karolina ^a   Mergancová, Jindriska ^a   Voboril, René ^a   Jandík, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Colorectal carcinoma; Hepatic arterial infusion; Liver metastases; Resection; Survival

Indexed keywords

CYTOTOXIC AGENT; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REVIEW;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CATHETERS, INDWELLING; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; PORTAL VEIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33745473797     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C: Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994. Eur J Cancer 1999; 35:1477-1516.
2. Lee CYTM: Carcinoma of the colon and rectum: Distribution of metastatic sites, risk factors and autopsy studies. GI Cancer 1998; 2:255-266.
3. Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Tanaka Y, Masuda T, Mukoyama S, Yasuda S, Tajima T, Makuuchi H, Murayama C: Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology 2003; 50:1362-1366.
4. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J: Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343:1405-1410.
5. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 1954; 30:969-985.
6. Venook AP, Warren RS: Regional chemotherapy approaches for primary and metastatic liver tumors. Surg Oncol Clin N Amer 1996; 5:411-427.
7. August DA: Theoretic and experimental aspects of regional liver infusion. Surg Oncol Clin N Amer 1996; 5:399-409.
8. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206:685-693.
9. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, Salmon R, Julien M, Roullet Audy JC, Gallot D, Gouzi JL, Pailler JL, Elisa D, Lacaine F, Roos S, Rotman N, Luboinski M, Lasser P: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992; 10:1112-1118.
10. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF, Rayner A, Ignoffo RJ, Acord P, Lewis BJ: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol 1989; 7:1646-1654.
11. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987; 107:459-465.
12. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J: Quality of life and survival with contnuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344:1255-1260.
13. Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88:252-258.
14. Harmantas A, Rotstein LE, Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996; 78:1639-1645.
15. Earlam S, Glover C, Davies M, Fordy C, Allen-Mersh TG: Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J Clin Oncol 1997; 15:2022-2029.
16. Fiorentini G, Poddie DB, Cantore M, Giovanis P, Guadagni S, De Giorgi U, Cariello A, Dazzi C, Turci D: Locoregional therapy for liver metastases from colorectal cancer: The possibilities of intraarterial chemotherapy, and new hepatic-directed modalities. Hepatogastroenterology 2001; 48:305-312.
17. Mathur P, Allen-Mersh TG: Hepatic arterial chemotherapy for colorectal liver metastases. Hepatogastroenterology 2001; 48:317-319.
18. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertion JR, Turnbull ADM, Sullivan D, Stockman J, Blumgart LH, Fong Y: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-2048.
19. Lorenz M, Muller HH: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus flurodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18:243-254.
20. Piedbois P, Zelek L, Cherqui D: Chemotherapy for non-operable colorectal liver metastases. Hepatogastroenterology 2001; 48:711-714.
21. Cunningham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
22. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
23. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Levi F: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-669.
24. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
25. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
26. Melichar B, Dvorak J, Jandik P, Touskova M, Malirova E, Mergancova J, Voboril Z: Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases - a pilot experience. Hepatogastroenterology 2001; 48:1721-1726.
27. Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE: Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141:586-589.
28. Petrelli NJ, Bonnheim DC, Herrera LO, Mittelman A: A proposed classification system for liver metastasis from colorectal carcinoma. Dis Colon Rectum 1984; 27:249-252.
29. Patanaphan V, Salazar OM: Colorectal cancer: Metastatic patterns and prognosis. Southern Med J 1993; 86:38-41.
30. van Riel JMGH, van Groeningen CJ, Albers SHM, Cazemier M, Meijer S, Bleichrodt R, van den Berg FG, Pinedo HM, Giaccone G: Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: Single-centre experience in 145 patients. Ann Oncol 2000; 11:1563-1570.
31. Kerr DJ, McArdle CS, Ledermann J, Taylor I, Sherlock DJ, Schlag PM, Buckels J, Mayer D, Cain D, Stephens RJ: Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicenter randomised trial. Lancet 2003; 361:368-373.
32. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306:752-755.
33. Lygidakis NJ, Sgourakis G, Dedemadi G, Safioleus MC, Nestoridis J: Regional chemoimmunotherapy for non-resectable metastatic disease of colorectal origin. A prospective randomized study. Hepatogastroenterology 2001; 48:1085-1087.
34. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF: Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938-946.
35. Asahara T, Kikkawa M, Okajima M, Ojima Y, Toyota K, Nakahara H, Ketayama K, Itamoto T, Marubayashi S, One E, Yahata H, Dohi K, Azuma K, Ito K: Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology 1998; 45:805-811.
36. Neeleman N, Wobbes T, Jager GJ, Ruers TJM: Cryosurgery as treatment modality for colorectal liver metastases. Hepatogastroenterology 2001; 48:325-329.
37. Kainuma O, Asano T, Aoyama O, Takayama W, Kakagohri T, Kenmochi T, Hasegawa M, Tokoro Y, Sasagawa S, Ochiai T: Combined therapy with radiofrequency thermal ablation and intra-arterial infusion chemotherapy for hepatic metastases from colorectal cancer. Hepatogastroenterology 1999; 46:1071-1077.
38. Hanazaki K, Kawamura N, Wakabayashi M, Sodeyama H, Yokoyama S, Sode Y, Miyazaki T: Long-term survivor with liver metastases from rectal cancer treated by hepatectomy after hepatic arterial infusion chemotherapy. Hepatogastroenterology 1998; 45:816-820.
39. Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, Faivre J: Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 1995; 82:1397-1400.
40. Palmer M, Petrelli NJ, Herrera L: No treatment option for liver metastases from colorectal carcinoma. Dis Colon Rectum 1989; 32:698-701.
41. Kemeny N, Niedzwiecki D, Shurgot B, Oderman P: Prognostic variable in patients with hepatic metastases from colorectal cancer. Importance of medical asessment of liver involvement. Cancer 1989; 63:742-747.
42. Finan PJ, Marshall RJ, Cooper EH, Giles GR: Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 1985; 72:373-377.
43. Aldrighetti L, Arru M, Ronzoni M, Salvioni M, Villa E, Ferla G: Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer. Hepatogastroenterology 2001; 48:1302-1307.
44. Makela J, Kantola R, Tikkakoski T, Sinoluoto T, Leinonen S, Kiviniemi H, Laitinen S, Kairaluoma M: Superselective intra-arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer. J Surg Oncol 1997; 65:127-131.
45. Link KH, Pillasch J, Formentini A, Sunelaitis E, Leder G, Safi F, Kornmann M, Beger HG: Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases. Eur J Surg Oncol 1999; 25:381-388.
46. Zanon C, Grosso M, Clara R, Alabiso O, Chiappino I, Miraglia S, Martinotti R, Bortolini M, Rizzo M, Gazzera C: Combined regional and systemic chemotherapy by a mini-invasive approach for the treatment of colorectal liver metastases. Am J Clin Oncol 2001; 24:354-359.
47. Cyjon A, Neuman-Levin M, Rakowsky E, Greif F, Belinsky A, Atar E, Hardoff R, Brenner B, Sulkes A: Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy. Brit J Cancer 2001; 85:504-508.
48. Welch JP, Donaldson GA: The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189:496-502.
49. Litvak DA, Wood TF, Tsioulias GJ, Chung M, Chawla SP, Foshag LJ, Morton DL, Ramming KP, Bilchik AJ: Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol 2002; 9:148-155.
50. Kirk Martin J, O Connell MJ, Wieand HS, Fitzgibbons RJ, Mailliard JA, Rubin J, Nagorney DM, Tschetter LK, Krook JE: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990; 125:1022-1027.
51. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 1997; 15:808-815.
52. Kemeny N, Cohen A, Seiter K, Conti JA, Sigurdson ER, Tao Y, Niedzwiecki D, Botet J, Budd A: Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993; 11:330-335.
53. Stehlin JS, de Ipolyi PD, Greeff PJ, McGaff CJ, Davis BR, McNary L: Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients. Ann Surg 1988; 208:23-35.
54. Link KH, Sunelaitis E, Kornmann M, Schatz M, Gansauge F, Leder G, Formentini A, Staib L, Pillasch J, Beger HG: Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival. Cancer 2001; 92:2746-2753.